SEC Form 4 · accession 0001209191-18-061791
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew R Patterson
Officer — Chief Executive Officer · Director
Period of report
Dec 6, 2018
Accepted (ET)
Dec 10, 2018 · 4:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 6, 2018 | M | 40,000 | $0.78 | A | 55,000 | D | |
| Common StockF1 | holding | — | — | — | 171,814 | I | By Matthew R. Patterson Revocable Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.78 | Dec 6, 2018 | M | 40,000 | D | — | Sep 25, 2023 | Common Stock | 40,000 | 31,702 | D |
Explanation of responses
- F1The reporting person is the trustee of the Matthew R. Patterson Revocable Trust.
- F2The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017.